Coronary Artery DiseaseMAGICAL SVNCT06271590
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
A study testing Sirolimus Drug Coated Balloon and Drug eluting stents (DES) in people with Coronary Artery Disease and Native Coronary Artery Stenosis, run by Concept Medical Inc. at 24 sites in United States.
Trial summary
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
- What is being tested?
- Sirolimus Drug Coated Balloon and Drug eluting stents (DES)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,605 participants
- Where
- 24 sitesUnited States
- Study dates
- 20 May 2025to Nov 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Clinical Inclusion Criteria:
- Adult patient with an indication for PCI due to stable angina, NSTEACS, post-infarction angina or silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, FFR ≤0.80, or non-hyperemic pressure ratio [NHPR] ≤0.89 must be present)
- Subject is ≥18 and <80 years old
- Subject is willing to comply with all protocol-required follow-up evaluations and provides written informed consent Angiographic Inclusion Criteria:
- Target reference vessel diameter (visual estimation) ≤2.75 mm
- Successful lesion preparation (residual stenosis <30%), without flow-limiting complications (no or slow flow, dissection etc.)
- Target lesion(s) in a native coronary artery
- Up to two small vessel target lesions in two different vessels
- Target lesion length (visual estimation): ≥6.0 and ≤34.0 mm and can be covered by a single 40 mm balloon
- Target lesion diameter stenosis (visual estimation) >30% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥2
Clinical Exclusion Criteria:
- Planned (staged) intervention in the target vessel
- ST-segment-elevation MI within 48 hours prior to index procedure
- Subjects with acute cardiac decompensation or cardiogenic shock
- Subject with a life expectancy of less than 24 months
- Impaired renal function (glomerular filtration rate [GFR] <30 mL/min)
- Documented left ventricular ejection fraction (LVEF) ≤30%
- Known allergies to acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, heparin, contrast medium, sirolimus or similar drugs (i.e., ABT-578 [Zotarolimus], biolimus, tacrolimus)
- Relative or absolute contraindication to dual antiplatelet therapy (DAPT) for at least 1 month (e.g., planned surgeries that cannot be delayed)
- Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor
- If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath
- Hemoglobin <9 g/dL
- Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
- White blood cell count <3,000 cells/mm3
- Active infection undergoing treatment
- Clinically significant liver disease
- Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA
- Subject is receiving oral or intravenous immunosuppressive therapy (e.g., inhaledsteroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
- Subject is unlikely to comply with the follow up requirements, per investigator's assessment
- Subject currently enrolled in other investigational device or drug trial in which primary endpoint has not been reached
- Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study Angiographic Exclusion Criteria: All exclusion criteria apply to the target lesion(s) or target vessel(s)
- Re-stenotic lesion(s), whether due to percutaneous old balloon angioplasty (POBA) or prior stenting
- True bifurcation lesion (lesion involves both main and side branch>2.5 mm) with planned treatment of both branches per investigator assessment
- Angiographic evidence of thrombus in the target vessel
- Myocardial bridging
- Target lesion is heavily calcified
- Diffuse distal disease to target lesion with impaired runoff, TIMI flow <2
- Non-target lesion in the target vessel requiring PCI
Note: Non-target vessel PCI is allowed at the time of index procedure if performed prior to study intervention and if successful and uncomplicated. For target lesions located in branches of the three main vessels (left anterior descending artery [LAD], left circumflex artery [LCx], right coronary artery [RCA]), the term target vessel refers to the branch and not the main vessel.
Trial locations and contacts
24 sites in 1 country. Contact the study team or a site near you to ask about taking part.
24 sites in 1 country
United States24 sites, 24 recruiting
- Not yet recruiting
Emory University Hospital /Emory School of Medice
Atlanta, Georgia, 30322
Mutsa Seremwe, 404-712-5622, mutsa.seremwe@emory.edu
- Not yet recruiting
University Hospitals, Cleveland Medical Center
Brooklyn, New York, 11215
Jhané Phanor, 917-679-1951, jhp4004@nyp.org
- Recruiting
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida, 33756
Jessica Cain, 727-467-9393, cainj@cccheart.com
- Not yet recruiting
University Hospitals, Cleveland Medical Center
Cleveland, Ohio, 44106
Stacey Mazzurco, 12169785519, Stacey.Mazzurco@uhhospitals.org
- Not yet recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
Claire Licina, 216-442-5574, licinac@ccf.org
- Not yet recruiting
Atlanta VA Medical Center
Decatur, Georgia, 30033
Susan Muly, 4042638204, Susan.Muly@va.gov
- Not yet recruiting
Dignity Health - Mercy Gilbert Medical Center
Gilbert, Arizona, 85297
Jennifer Zumbuhl, 480-728-9973, Jennine.Zumbuhl@commonspirit.org
- Not yet recruiting
University of Florida Health Sciences Center-Jacksonville
Jacksonville, Florida, 32209
Andrea Burlton, 904-244-5617, andrea.burton@ufhealth.org
- Not yet recruiting
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Mitch Gheorghiu, 310 4236152, mitch.gheorghiu@cshs.org
- Not yet recruiting
North Shore University Hospital - Northwell
Manhasset, New York, 11030
Emma Graze, 516-562-4100, clinicalresearch@northwell.edu
- Not yet recruiting
Loyola University Medical Center
Maywood, Illinois, 60153
Tracy Bielecki Smith, 7083272761, tbielecki@luc.edu
- Not yet recruiting
West Virginia University Heart & Vascular Institute
Morgantown, West Virginia, 26506
Kimberly Quedado, 304-285-1980, Kimberly.Quedado@wvumedicine.org
- Recruiting
Icahn School of Medicine at Mount Sinai/ Mount Sinai Hospital
New York, New York, 10029
Nimisha Baruah, 212-241-9687, nimisha.baruah@mountsinai.org
- Not yet recruiting
Columbia University/NYP
New York, New York, 10032
Treena Williams, 212-342-3485, taw2112@cumc.columbia.edu
- Not yet recruiting
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, 73104
Aurora Vera, 405-308-3570, Aurora-Vera@ouhsc.edu
- Not yet recruiting
University of Pittsburgh Medical center (UPMC)
Pittsburgh, Pennsylvania, 15123
Kristin Shoemaker, 412-692-2769, shoeka@UPMC.EDU
- Recruiting
Baylor Scott & White The Heart Hospital - Plano
Plano, Texas, 75093
Walter Cerqueira, 817-922-2586, walter.cerqueira@bswhealh.org
- Recruiting
Atlanticare Regional Medical Center
Pomona, New Jersey, 08401
Jacqueline White, 609-404-7654, JMWhite@atlanticare.org
- Not yet recruiting
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Bethany Wilson, 503-2167275, bethany.wilson@providence.org
- Not yet recruiting
NC Heart and Vascular Research, LLC
Raleigh, North Carolina, 27607
Rebecca Palermo, (919) 745-0750, Rebecca.palermo@unchealth.unc.edu
- Not yet recruiting
Tallahassee Research Institute
Tallahassee, Florida, 32308
Wendie Najdowski, 850-431-5024, Wendie.Najdowski@tmh.org
- Not yet recruiting
Tampa General Hospital / University of South Florida
Tampa, Florida, 33606
Gabriel Parker, (813) 810-5700, gparker4@usf.edu
- Recruiting
Montefiore Medical Center
The Bronx, New York, 10467
Regina Hanstein, 646-648-6125, hanstein@montefiore.org
- Not yet recruiting
North Mississippi Medical Center
Tupelo, Mississippi, 38801
Yvonne Ray, (662) 377-5447, YRay@nmhs.net
About this study
Official title: The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).
A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of ~50% of enrollees.
Read the detailed description
Subjects with small vessel CAD (Coronary artery disease) presenting with lesions undergoing PCI (Percutaneous coronary intervention) will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or DCB (drug-coated balloon) on a 2:1 basis. Approximately 1605 subjects will be enrolled in the randomized study.
Treatment of a single lesion in a single major coronary artery or side branch will be enrolled per the inclusion and exclusion criteria. Target lesion must be located in a native coronary artery with a visually estimated diameter of<2.75 mm to length (including tandem lesions) ≤34.0 mm by visual estimation, and diameter stenosis ≥50% to <100% in symptomatic patients or ischemia by coronary physiology in patients without symptoms. The primary endpoint is TLF (target lesion failure) at 12 months after intervention.
All subjects providing informed consent will have their medical history reviewed and will undergo a physical examination, laboratory screen, and a standardized 12-lead ECG within 7 days of procedure. Women of childbearing potential will have a pregnancy test within one week prior to the procedure. SAQ-7 (Seattle Angina Questionnaire) will be collected at baseline, 30 days, 6 months, and 12 months and prior to any planned intervention.
- Being tested
- Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
- Keywords
- Drug coated balloon, Sirolimus coated balloon, De Novo, Magic Touch, SCB, Concept Medical, Small Vessel, MAGICAL SV
- Medical subject headings
- Coronary Artery Disease, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sirolimus Drug Coated BalloonDevice
Also called Drug coated Balloon
Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
Drug eluting stents (DES)Device
For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
| Study group | Role | What they receive |
|---|---|---|
| MagicTouch Sirolimus-Coated Balloon (SCB) | Experimental | Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold. Receives: Device: Sirolimus Drug Coated Balloon |
| Drug eluting stents (DES) | Active comparator | Everolimus eluting stents (EES) or Zotarolimus eluting stents (ZES) Receives: Device: Drug eluting stents (DES) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Target lesion failure (TLF)
the composite of cardiovascular mortality, target-vessel myocardial infarction (TV-MI) and ischemia driven target lesion revascularization
Measured: within 12 months
Secondary outcomes (20)
Procedural success
defined as residual diameter stenosis <30% (DS), no flow-limiting dissection and with post-procedure The thrombolysis in myocardial infarction (TIMI) 3 flow, without the need for bailout stenting
Measured: at baseline, during the procedure
Target lesion failure (TLF)
defined as the composite of cardiovascular mortality, target-vessel myocardial infarction (TVMI) and ischemia driven target lesion revascularization
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Ischemia driven target vessel revascularization (ID-TVR)
Repeat revascularization of the target lesion due to recurrent ischemia
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel revascularization (TVR)
Repeat revascularization of the target vessel
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any revascularization
any repeat PCI
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel failure (TVF)
defined as the composite of cardiovascular mortality,ischemia driven TVR and TVMI
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Q-wave myocardial infarction (MI)
Myocardial Infarction demonstrated by new pathological Q waves on ECG
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Non Q-wave myocardial infarction (MI)
Myocardial Infarction not demonstrated by new pathological Q waves on ECG
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any myocardial infarction (MI)
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel myocardial infarction (TV MI)
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Spontaneous myocardial infarction (MI)
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Procedural myocardial infarction (MI)
Measured: Evaluated at 48 hours
Cardiovascular mortality
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Cardiovascular mortality or myocardial infarction (MI)
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality or MI
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality, myocardial infarction (MI) or target vessel revascularization (TVR)
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any probable or definite stent thrombosis
Measured: Evaluated at 48 hours
Probable stent thrombosis
Defined as per the Academic Research Consortium (ARC) criteria
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Definite stent thrombosis
Defined as per the Academic Research Consortium (ARC) criteria
Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2024
- Study start20 May 2025
- Primary completionNov 2028 (estimated)
- Study completionNov 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 2:1 randomized trial (MagicTouchTM Sirolimus-Coated Balloon VS Drug eluting stent (ZES or EES)
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 1,605 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Concept Medical Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Cardiovascular Research Foundation, New York
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06271590
- Sponsor's protocol ID
- CM-US-R03
- Acronym
- MAGICAL SV
- Status last verified
- Sep 2025
- First submitted
- 13 Feb 2024
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.
- ClinicalTrials.gov ID
- NCT06271590
- Acronym / sponsor ID
- MAGICAL SV / CM-US-R03
- Keywords
- Drug coated balloon, Sirolimus coated balloon, De Novo, Magic Touch, SCB, Concept Medical, Small Vessel, MAGICAL SV
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,605 participants (estimated)
- Lead sponsor
- Concept Medical Inc.Industry (pharma, biotech, devices)
- Collaborators
- Cardiovascular Research Foundation, New York
- Study start
- 20 May 2025 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2031 (estimated)
- First posted
- 22 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).
A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of ~50% of enrollees.
Detailed description
Subjects with small vessel CAD (Coronary artery disease) presenting with lesions undergoing PCI (Percutaneous coronary intervention) will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or DCB (drug-coated balloon) on a 2:1 basis. Approximately 1605 subjects will be enrolled in the randomized study.
Treatment of a single lesion in a single major coronary artery or side branch will be enrolled per the inclusion and exclusion criteria. Target lesion must be located in a native coronary artery with a visually estimated diameter of<2.75 mm to length (including tandem lesions) ≤34.0 mm by visual estimation, and diameter stenosis ≥50% to <100% in symptomatic patients or ischemia by coronary physiology in patients without symptoms. The primary endpoint is TLF (target lesion failure) at 12 months after intervention.
All subjects providing informed consent will have their medical history reviewed and will undergo a physical examination, laboratory screen, and a standardized 12-lead ECG within 7 days of procedure. Women of childbearing potential will have a pregnancy test within one week prior to the procedure. SAQ-7 (Seattle Angina Questionnaire) will be collected at baseline, 30 days, 6 months, and 12 months and prior to any planned intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- 2:1 randomized trial (MagicTouchTM Sirolimus-Coated Balloon VS Drug eluting stent (ZES or EES)
| Arm | Type | Receives |
|---|---|---|
| MagicTouch Sirolimus-Coated Balloon (SCB) | Experimental | Device: Sirolimus Drug Coated BalloonMagic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold. |
| Drug eluting stents (DES) | Active comparator | Device: Drug eluting stents (DES)Everolimus eluting stents (EES) or Zotarolimus eluting stents (ZES) |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sirolimus Drug Coated BalloonAlso: Drug coated BalloonMagic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology. | Device | MagicTouch Sirolimus-Coated Balloon (SCB) |
| Drug eluting stents (DES)For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices. | Device | Drug eluting stents (DES) |
Primary outcome
Target lesion failure (TLF)
Time frame: within 12 months
the composite of cardiovascular mortality, target-vessel myocardial infarction (TV-MI) and ischemia driven target lesion revascularization
20 secondary outcomes
Procedural success
Time frame: at baseline, during the procedure
Target lesion failure (TLF)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Ischemia driven target vessel revascularization (ID-TVR)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel revascularization (TVR)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any revascularization
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel failure (TVF)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Q-wave myocardial infarction (MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Non Q-wave myocardial infarction (MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any myocardial infarction (MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Target vessel myocardial infarction (TV MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Spontaneous myocardial infarction (MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Procedural myocardial infarction (MI)
Time frame: Evaluated at 48 hours
Cardiovascular mortality
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Cardiovascular mortality or myocardial infarction (MI)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality or MI
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
All-cause mortality, myocardial infarction (MI) or target vessel revascularization (TVR)
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Any probable or definite stent thrombosis
Time frame: Evaluated at 48 hours
Probable stent thrombosis
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Definite stent thrombosis
Time frame: 30 days and at 6, 12, 24, 36, 48, and 60 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
24 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sirolimus Drug Coated Balloon and Drug eluting stents (DES) in people with Coronary Artery Disease and Native Coronary Artery Stenosis, run by Concept Medical Inc. at 24 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 24 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Farhana Siddique (+919725495366, farhana@conceptmedical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Target lesion failure (TLF) (time frame: within 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.